It has been suggested that the activation of NF-κB plays a crucial role in the regulation of immune and inflammatory responses, and thus inhibiting the NF-κB signaling pathway is a novel therapeutic strategy in IBD treatment research. The gene discussed is NFKB1; the disease is inflammatory bowel disease.